Business Context and Reporting Period
Pavmed Inc. (PAVM), an emerging growth company, filed this Form 8-K on August 12, 2021. The filing serves as a current report to disseminate a business update regarding the Company and its major subsidiary, Lucid Diagnostics Inc. The financial results referenced in this filing cover the three and six months ended June 30, 2021.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K.
Material Changes
This report does not explicitly detail material changes versus prior periods within the text provided. It directs investors to the attached press release for a discussion of financial results and business updates for the periods ended June 30, 2021.
Guidance, Outlook, and Risks
Management commentary, outlook, and specific risk factors are not enumerated in this filing. The document notes that the information furnished under Item 2.02, including the attached press release, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference in other disclosure documents unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for the three and six months ended June 30, 2021.
- Verify the operational status and strategic updates for the subsidiary, Lucid Diagnostics Inc.
- Confirm the trading status of Common Stock (PAVM) and Warrants (PAVMZ, PAVMW) on The Nasdaq Stock Market LLC.
- Note that the financial data in the press release is not legally "filed" under Section 18 of the Exchange Act per the terms of this 8-K.